---
layout: default
title: Lefamulin Acetate
parent: 僅模型預測 (L5)
nav_order: 60
evidence_level: L5
indication_count: 0
---

# Lefamulin Acetate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lefamulin Acetate: Evaluation Report — Insufficient Data for Repurposing Assessment

## One-Sentence Summary

Lefamulin Acetate is a drug with no active Taiwan market authorization found in this dataset.
The TxGNN model returned **no predicted new indications** for this compound in the current pipeline run,
and critical data including original indication, mechanism of action, and safety profile are all missing — making a full repurposing evaluation impossible at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predictions were returned for Lefamulin Acetate in this pipeline run. Without a predicted indication, a mechanistic rationale analysis cannot be constructed.

Additionally, the mechanism of action (MOA) data is currently unavailable. Without knowing how this drug works at the molecular level, it is not possible to establish a plausible biological link between any original and new indication.

To unblock this section, the following data must be retrieved first: DrugBank MOA entry, original approved indication text (from TFDA package insert or global regulatory databases), and a re-run of the TxGNN pipeline after confirming the drug's graph node mapping is correct.

---

## Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication available to query against).

---

## Literature Evidence

Currently no related literature available (no predicted indication available to query against).

---

## Taiwan Market Information

No authorizations found. Lefamulin Acetate has **0** active licenses in the Taiwan TFDA database as of the data cutoff (2026-04-20).

---

## Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug-drug interactions) returned no usable data in this pipeline run.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The current Evidence Pack contains no TxGNN-predicted indications, no original indication text, no MOA, and no safety data — there is no evaluable basis for a repurposing recommendation at this time.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve TFDA package insert (仿單) to extract approved indication text, key warnings, and contraindications; the TFDA official website has a confirmed result (query ID 4 returned success, result count 1 — the PDF needs to be parsed)
- **[High — DG002]** Query DrugBank API to obtain the mechanism of action; query ID 3 also returned success with 1 result — this data needs to be extracted and populated
- **[Pipeline]** Confirm that Lefamulin Acetate has a valid node mapping in the TxGNN knowledge graph; the empty `predicted_indications` array suggests the compound may not be mapped or scored — verify node ID and re-run the prediction step
- **[Regulatory]** Check international regulatory status (FDA, EMA) to establish original indication baseline if TFDA data remains sparse
- Once the above gaps are resolved, re-generate the Evidence Pack and re-evaluate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

